Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcript
November 2, 2026
Earnings Call Speaker Segments
Thank you, and happy Monday to everyone, no matter where you're joining from. You're listening to the Neurocrine Biosciences Third Quarter 2026 Earnings Call. With me today are Kyle Gano, our Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Eiry Roberts, Chief Medical Officer; and Samir Siddhanti, Chief Business Officer. On this call we'll be making forward-looking statements. Such statements carry certain risks and uncertainties, and actual results could differ materially. Please review the risk factors covered in our most recent SEC filings. Also, certain information we discuss today includes non-GAAP financial measures that were not calculated in accordance with U.S. GAAP. You'll find reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables at the end of our earnings release issued earlier today, which is posted on the Investor Relations page of the company's website. After our prepared remarks, we'll be glad to take your questions. With that, I'll turn the call over to Kyle.
Good afternoon, everyone. Almost 2 years back, on my first earnings call as CEO, I expressed optimism regarding Neurocrine's future and the considerable opportunities in front of us. That confidence has only strengthened since then, and I remain deeply convinced of our capacity to deliver sustained growth and build long-term value for shareholders. Our plan to create a leading biopharmaceutical company rests on execution and on producing meaningful results. During the third quarter, we posted record net product sales exceeding $1.1 billion along with record profitability. Those results highlight how strong our diversified portfolio of 3 first-in-class medicines is, and how our ability to reach and serve more patients than ever keeps expanding. This momentum leaves us well positioned to drive continued growth across INGREZZA, CRENESSITY and VYKAT XR in 2027 and beyond. The strength of our growing commercial business and our financial position also lets us keep investing in our industry-leading pipeline; with several important clinical milestones expected in 2027, including Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we believe Neurocrine is nearing a potentially transformative period — one that could further expand our pipeline, bolster our long-term growth prospects and widen our impact on patients. All in all, Neurocrine's third quarter performance demonstrates the strength of our strategy, the discipline behind our execution and the considerable opportunity ahead to create long-term value. As we close out the year, we look forward to hosting our 2026 R&D Day in New York City on December 15. The event will include a VYKAT XR panel discussion with Dr. Jennifer Miller, Professor of Pediatric Endocrinology and Director of the Prader-Willi syndrome program at the University of Florida College of Medicine, plus an update on our pipeline. I'm eager to share our progress, engage with the investment community and talk through the opportunities ahead as we enter what promises to be a catalyst-rich 2027. With that, I'll hand the call over to Matt.
Thank you, Kyle, and good afternoon to all of you. Q3 shows Neurocrine continuing to transform into a biopharmaceutical company that is diversified and highly profitable. As Kyle noted, we posted record net product sales above $1.1 billion, a rise of over 40% versus a year ago, together with record operating profitability. Our 3 commercial products give us a growing base for investing in innovation and getting ready for a data-rich 2027. To begin with INGREZZA. Q3 sales came in at $801 million, 17% higher than a year earlier, powered by ongoing volume gains with record new and total prescriptions. INGREZZA's underlying performance keeps surpassing our own internal expectations, which leads us to raise full year INGREZZA guidance once more, to $2.9 billion to $2.925 billion. Q3 sales contained a $20 million benefit from customer order timing, something we expect to reverse in Q4 and which is reflected in our full year guidance. All in all, 2026 is proving a remarkable year for INGREZZA, with prescription growth anticipated in the high-teens, underscoring how strong and durable the INGREZZA franchise is in the tardive dyskinesia market. As we look toward 2027, we anticipate continued double-digit volume growth for INGREZZA that should more than offset expected mid- to high single-digit net pricing headwinds, supporting yet another year of revenue growth. We'll keep with tradition and provide formal sales guidance for 2027 in February. CRENESSITY recorded $211 million in sales for Q3, supported by consistent gains in patient numbers, solid persistence and favorable reimbursement. Prescriptions for CRENESSITY now cover over 15% of the estimated diagnosed classic CAH population, underscoring the opportunity that remains ahead of us; Q3 sales for VYKAT XR came to $107 million, showing sequential growth driven by demand from new patients. Our focus continues on efforts supporting appropriate patient identification, education for physicians and caregivers, and patient support. We believe VYKAT XR offers a meaningful long-term growth opportunity to help many patients living with this devastating condition. Turning to the financials, record revenue pushed non-GAAP earnings above $3 per share. That demonstrates meaningful operating leverage even as we keep funding commercial expansion and our R&D pipeline; we ended the quarter holding roughly $800 million in cash, produced $400 million of operating cash flow, and allocated about $100 million toward share repurchases to offset dilution caused by share-based compensation. Driving commercial growth, moving high-value pipeline programs forward, and pursuing disciplined business development remain our capital allocation priorities. All in all, with 3 commercial products growing, profitability expanding, and a broad pipeline, Neurocrine is well positioned for durable growth and important clinical catalysts in 2027. With that, I'll hand the call to Eric Benevich, our Chief Commercial Officer. Eric?
Appreciate that, Matt. For us, the third quarter set a new record, reflecting robust performance from all three of our first-in-class medicines — INGREZZA, CRENESSITY and VYKAT XR. Although each occupies a distinct stage in its commercial journey, all three continue to serve major unmet medical needs while contributing to Neurocrine's commercial diversification and revenue growth. Starting with INGREZZA: for the first time, quarterly sales exceeded $800 million, driven by strong demand and record new and total prescriptions. Notably, nine years after launch, INGREZZA continues to deliver double-digit prescription growth, and we have once again raised full year sales guidance — 2026 appears poised to be another outstanding year for the brand. CRENESSITY also reached a fresh milestone, exceeding $200 million in quarterly sales for the first time. Throughout the year, new patient starts have remained stable, and we believe that over 15% of U.S. patients with classic congenital adrenal hyperplasia have now received a CRENESSITY prescription. Just 7 quarters into the launch, we are achieving meaningful progress toward making CRENESSITY, along with low-dose GCs, the standard of care treatment for classic CAH. Turning now to VYKAT XR, quarterly sales exceeded $100 million for the first time. From the time we completed the acquisition, our commercial and medical groups have focused on educating HCPs — addressing suitable PWS patient selection, dose titration, vigilant monitoring and handling of possible adverse events, and setting expectations regarding when and how treatment response may appear. Such work demonstrates how dedicated we are to the best possible patient safety and treatment outcomes. Being new to the PWS community, we are hearing from every stakeholder group and learning from clinicians, PWS scientific thought leaders, and the Prader-Willi syndrome patient and family community. We have confidence in VYKAT XR's benefit and in what it can achieve over the longer term within our rare endocrine franchise. There is no doubt that 2026 will turn out to be the strongest commercial year in Neurocrine's history, and we look forward to bringing that momentum forward into 2027. I'd like to express gratitude to everyone across our commercial and medical teams—among them the colleagues who recently joined us through VYKAT XR—for their steadfast commitment to patients and for executing so well. With that said, I'm glad to hand things over now to Dr. Eiry Roberts, our Chief Medical Officer.
Thanks, Eric, and good afternoon to all of you. First off, I'd like to express my appreciation to Kyle and the Board of Directors for giving me the chance to come back as Chief Medical Officer. In my prior time here, it was a privilege to contribute to moving CRENESSITY forward through clinical development and approval, and also to generating positive Phase II data and kicking off the Phase III programs for osavampator and direclidine. I'm eager to carry forward the team's recent momentum as we push ahead the deepest and most diversified pipeline in Neurocrine's history. I'd like to start today with VYKAT XR, the first and only FDA-approved treatment for hyperphagia in patients age 4 and older with Prader-Willi syndrome. Since Neurocrine acquired this medicine in May, our clinical and medical teams have collaborated closely with expert clinicians, regulators and the PWS community to support safe and appropriate use of this important new medicine. As real-world experience accumulates, we stay committed to ongoing safety monitoring, working with the FDA and communicating important new information in a timely way. To deepen our understanding further, we intend to launch a study in 2027 evaluating VYKAT XR in people with PWS and complex health issues. Continued engagement with advocacy organizations, including FPWR and PWSA USA, also remains central to our efforts. Turning to the pipeline, we recently began a Phase II study of NBI-'567, our M1-preferring selective muscarinic agonist, as an adjunctive treatment for cognition in Alzheimer's disease; in obesity, we started a Phase I study of NBIP-'1968, our investigational GGG agonist; this program could complement our CRF2 agonist, NBIP-'2118, which is also in Phase I, as we explore differentiated combinations for treating obesity. Lastly, NBIB-223, our Friedreich's ataxia gene therapy program done in collaboration with Voyager Therapeutics, should enter Phase I in the coming months, with initial patient-level data expected in 2027. As Kyle mentioned, we'll wrap up the year with our 2026 R&D Day in New York City on December 15. I'm looking forward to sharing our progress and reengaging with the investment community as we gear up for a data-rich year in 2027. With that, I'll hand it back to Todd. Todd?
Thanks, Eiry, and welcome back to the role. We're glad to have you with us. Sorry that today's earnings release went out a little later than planned. We appreciate everyone's patience and look forward to your questions; so Nicki, let's take the questions.
Congratulations on a very strong quarter. My question is about INGREZZA trends and guidance. If we exclude the $20 million of orders you mentioned this quarter, even after removing that, it does appear that the high end of guidance implies a Q4 that's down sequentially, so I suppose we're wondering why that would be? Was there anything else lumpy in Q3 besides the $20 million? Or do you expect other headwinds for INGREZZA in the fourth quarter?
The third quarter was very strong across the board, and in the fourth quarter we'd expect similar underlying TRx growth, somewhere in the mid-teens. So the other — the only other factor is that seasonally, the fourth quarter always has a gross-to-net dynamic. But overall, if you take a step back, you see we began the year with guidance of $2.7 billion and raised it all the way to $2.9 billion, we feel quite good about how we're positioned, and we're in a place to carry strong momentum into 2027.
Congratulations on the quarter. I'd like to ask something about VYKAT. Of course, its safety profile has been talked about in the media and the press. From where you sit, I'm curious: are you confident that over the coming quarters VYKAT will keep growing in a resilient way? And perhaps, as a follow-up, has there been any consideration of engaging with regulators at some point regarding some of the post-marketing safety reports? Maybe you could give a bit of color on that.
Yes. Paul, this is Eric. Well, certainly we understand that with orphan diseases, launches don't always follow a linear path. And I believe we're roughly 2.5 quarters past the acquisition at this point. So we're still getting our arms around the VYKAT business. And we remain right in the middle of the integration. That said, in light of the recent external events, we do expect a return to growth, though it may be somewhat more delayed. At the end of the day, we still hold very strong conviction in the benefit of VYKAT, and we're working to make sure that everyone understands both the benefits and how to use it safely. Anything to add?
Yes. Thanks, Paul. I mean, patients remain with Neurocrine. So every adverse event and every outcome is taken very seriously by us, and we monitor safety on a continuous basis as we — within the post-marketing setting. That being said, our confidence is very high in the benefit-risk profile we have for VYKAT XR. And we believe the current label describes, quite effectively, how to use the medicine safely and effectively in the relevant patient population. Obviously, we keep gathering information on an ongoing basis. And in particular, I'd point you to what we mentioned at the end of this year at our R&D Day: we will focus on understanding PWS — and hyperphagia especially — more for the community by engaging with Dr. Jennifer Miller and several patients from the community. And I think that will be helpful in that regard. In addition, we are planning to initiate a study starting next year in patients with Prader-Willi who also have significant other comorbidities and other conditions that make them, obviously, at higher risk generally in terms of their disease, to understand how to safely and effectively use VYKAT XR in that population.
I was hoping you could give us some color on the 2027 INGREZZA contracting—specifically, whether access and net price are holding up or tracking in line with what you'd have expected. Any color there would be great.
Thanks, Tazeen. Kyle here. It's tough to discuss 2027 pricing without beginning with access, since the two are connected. For this year, as you're aware, roughly 70% of Medicare lives are covered under the contracting we put in place in 2025, and that generated strong momentum for us throughout this year, and we believe that will remain the case as we finish Q4 and head into 2027. So as we think about 2027, we do expect that underlying momentum to produce, again, double-digit volume growth for 2027, and that really underscores the durability of INGREZZA as a product in TD, along with continued revenue growth. Now, on contracting for 2027, we're nearly at the end—at the conclusion of our discussions with payers. We have fairly good visibility regarding our formulary status for 2027. And what we're seeing is a really strong year when it comes to coverage and access to lives, at least as good as this year. So we're anticipating a really strong access year for 2027. As for net price, we'll get into those details as we move into the new year. But roughly speaking, we're looking at a mid- to high single-digit price concession for 2027, though that will be more than offset by our double-digit revenue growth for next year. So this will play out in our assessment of performance as we move through Q4 into the new year when we discuss guidance at our February meeting; but overall, a really strong year lies ahead for 2027.
Hi, it's Kevin, covering for Brian. Maybe going back to VYKAT — since this quarter is the first complete one with VYKAT, could you tell us your latest take on what you're seeing on the ground? How could the potential opportunity — the peak opportunity — in PWS be taking shape? Are your thoughts a bit more refined at this point, and what would that opportunity look like, plus the timelines surrounding it?
Certainly; it's Eric here. So, stepping back and considering the Prader-Willi population, we figure there are approximately 10,000 to 12,000 patients across the U.S. The majority of them experience hyperphagia — although not all do. Clearly, hyperphagia usually doesn't show up in very young patients until around age four, five, or six. And as Eiry mentioned, some patients wouldn't be deemed suitable for treatment because of significant comorbidities. In the end, however, we believe the majority of patients with hyperphagia secondary to PWS are candidates for treatment. This medication is still fairly early in its launch—it's been available for just over a year and a half—and there are many providers in the community we're still reaching and educating, as well as within the patient and family community. So I'm not sure we've really changed how we think about the opportunity. Our confidence in what this drug can do remains very high. It is, as you're aware, the only therapy cleared for hyperphagia and PWS and the first of its kind, though we fully understand that substantial effort lies before us when it comes to education and to producing further evidence that shows how this drug is best deployed.
Congratulations on an excellent quarter. Perhaps regarding VYKAT, you brought up growth stemming from new patient starts, but I was hoping to hear whatever you can share regarding discontinuations. I understand there's this kind of bolus effect on new patient starts at launch that runs into possibly a headwind when it comes to discontinuations from that initial bolus once those patients reach therapy. Do you believe we've moved past that now? And do you anticipate a more typical count of patients discontinuing each quarter, since that roll-off no longer stems from the initial bolus? I just want some sense of how to think about the balance between starts and discontinuations at this point?
Yes. I'd say — let me begin by noting that we're still learning about the dynamics at play here. As I said, this product has been on the market for only a bit more than 1.5 years. And certainly, there was a bolus of starts in the first quarter or 2 when VYKAT was launched last year. And then we did observe something of a rise in discontinuations from that bolus of early starting patients. Since then, we've seen starts that are fairly consistent and steady. And it's difficult to say whether Q3 differed in any way from a discontinuation standpoint, because numerically, it was similar to prior quarters. So I'd say stay tuned.
Congratulations on the quarter. Look, it was a solid beat on INGREZZA, and even if you take out that $20 million one-timer, it was — it's still going to beat consensus; so is there any outsized growth in the various segments — psychiatry, neurology, long-term care — that you'd want to call out?
Yes. Thanks for the question. I think you're seeing growth potential in all the prescriber segments. And as we've said previously, most patients out there with tardive dyskinesia have yet to be — well, we're actually getting close to a point where roughly half of the patients out there have been diagnosed and the remaining half have not been diagnosed yet, but there's still meaningful opportunity to drive diagnosis, recognition and treatment. On top of that, only about 10-ish percent of the total TD prevalent population is currently on either of the 2 VMAT2 inhibitors. So there's plenty of headroom from a growth potential standpoint. Obviously, we view the psychiatry segment as the primary growth driver; and within psychiatry, advanced practice providers in particular really matter when it comes to recognizing and treating TD with INGREZZA. So I think that reflects, in a way, how our sales team is deployed. The largest team is focused on psychiatry; we've also seen really strong and consistent growth in long-term care. So we're excited about the opportunity. As Kyle said earlier, we're going to carry the momentum into 2027. But we expect continued strong volume growth across all the segments — psychiatry, neurology and long-term care.
This is Josh filling in for Cory. On CRENESSITY, growth has been quite steady. I was wondering whether you could speak to where that growth is coming from? Are these new prescribers? Are they returning prescribers? Any detail you can share?
Yes. CRENESSITY has been remarkably consistent. From the earliest days of the launch, we've witnessed a very steady pace of patient adds; we've also witnessed favorable reimbursement. And finally, and critically important, really strong persistence. And I believe all of those elements together have produced what has been a really strong launch in the first — we're now a year and 3 quarters into the CRENESSITY launch. So it's still early in its commercial ramp. But ultimately, at the very start of the launch, most of the growth came from new prescribers. And to this day, the majority of prescribers still have only 1 or 2 patients that are on treatment. However, we are seeing increased depth of prescribing. And so as we move forward, those practices that have more than a handful of patients we're continuing to drive adoption of the majority of their patients within those practices. So we've done a really great job, I think, in the pediatric endocrinology segment; and that does represent the majority of patient starts. However, as of late, we've continued to see growth and adoption of — within the adult endo practices. And now we're at a point where roughly half the patients out there on CRENESSITY are adult patients; so we're going to continue to do our work. We're going to drive education and we've got a lot of remaining opportunities. As we said in the prepared remarks, over 15% of the population with Classic CAH has now been offered treatment and are on medicine.
Congratulations on the quarter, and it's good to have you back, Eiry. I'm looking forward to December when we'll all get together. Our question concerns 567. Now that the Phase II study has been initiated, could you describe what result on the 12-week neuropsychological test battery would count as clinically meaningful.
It's good to be back. Regarding 567, that compound is our M1 preferring muscarinic agonist. As you said, that trial is a Phase II study that just began, enrolling around 135 adults between the ages of 50 and 85 who have moderate — mild to moderate Alzheimer's disease, are on stable treatment with acetylcholinesterase inhibitors, yet continue to show evidence of cognitive decline. Within the study we're in fact examining a range of different endpoints, assessing change from baseline at week 12 for that adjunctive treatment. The primary endpoint we're evaluating is a composite score from the neuropsychological test battery, and the aim will be to compare the 2 treatments in the study against placebo and to look for any clinically significant trend or statistical significance in the difference versus placebo on that endpoint. Beyond that, though, we intend to examine the totality of the data generated in that study, which includes ADAS-Cog measurements and clinical dementia rating, along with tolerability of course, since in this patient population using acetylcholinesterase, tolerability is 1 of the most significant issues affecting use of that medication today. We haven't spoken specifically about bars or barriers to — regarding the endpoints, but clearly, we'll be taking a holistic look at the data we generate.
This is Phoebe, calling in for Akash. We had a question about the announcement of a 5x higher dose of emraclidine in the Phase II schizophrenia study? So first, what's your take on that, given there's sort of an unclear dose response in the emraclidine and NBI-'568 data. And then too, could you share some thoughts on where you think the comparable M4 inhibition levels for emraclidine at this dose stack up against your 20-milligram dose? And last, what's your overall confidence heading into the schizophrenia readout next year?
Phoebe, it's Samir. Thanks so much for the question. So we have direclidine, our M4 selective orthosteric agonist, and we expect top line data from the first short-term study next year — timelines remain on track there. We're really excited about those data relative to what's out there — looking at the competitive landscape, we believe this could offer potential benefit to patients without some of the side effects that they're experiencing with the existing commercial product, Cobenfy. As for your questions about other competitors such as AbbVie with emraclidine, we're certainly watching that landscape and wish them the best; but right now, our focus is on our program. Thank you.
Susan here, filling in for Mohit. Regarding VYKAT this quarter, you folks mentioned trends looked comparable, yet you clearly outperformed what was expected. Could you speak briefly about where some of that upside originated? Was it pricing, inventory, or net adds?
Right. What I'd say is that we finished the quarter with a larger number of patients receiving treatment than when we began it. So the driver is net adds, rather than pricing.
Sorry — I was quite brief, so if I may. What's the rationale for running this additional Prader-Willi study in patients with comorbidities — is it mostly for medical education and just answering some of those questions, or could there be an opportunity for label expansion?
In our view, the current label fairly captures VYKAT XR's benefits and risks in the population that was studied; and we do think there's room for education, particularly around how the right patients with hyperphagia in Prader-Willi syndrome are chosen for treatment with VYKAT XR? Beyond that, there's the matter of titration—how to do it safely and effectively—along with knowing how to keep a closer watch for adverse events that could emerge during treatment and how to handle them well from the very start. Another point worth stressing: our knowledge of hyperphagia in Prader-Willi syndrome remains fairly limited. That means we have considerable educating to do—helping people grasp what hyperphagia is and how it affects both the patient and the family. It is very much a behavioral disorder. Given that, we need to set expectations about the kinds of behavioral changes we can anticipate in patients as this medicine eases their hyperphagia symptoms. Given all that, we want to keep growing what we know about patients receiving VYKAT, including people dealing with additional complicated conditions like obesity, breathing issues, and so on. Thanks.
As we go through 2027, how would you lay out your main priorities for business development and M&A? Kyle, I believe earlier this year you mentioned that after Soleno we were over-indexed in psychiatry. Do you still feel that way, and which therapeutic areas inside your core focus areas are you prioritizing?
Thanks, David. I appreciate the question. Perhaps I'll ask Samir to offer his thoughts here.
Samir here. On the BD front, what I’d say is we genuinely intend to stay disciplined and focused when it comes to future opportunities. We’re seeking out opportunities that offer differentiated, innovative science along with strong IP in the areas where we have expertise. Right now we describe those as neurology, psychiatry, endocrinology, and immunology before long here. Any transactions we examine need to deliver value for our shareholders. So we stay engaged and ready to move should something opportunistic arise. We have considerable financial flexibility. It doesn’t feel to us as though we must complete a deal at this moment.
This is Alyssa, filling in for Mark. Regarding CRENESSITY, would you discuss discontinuation rates for the third quarter compared with earlier quarters? And what's your thinking on persistency trends going forward? Also on VYKAT, could you share where things stand with the current dose distribution — which maintenance doses are used most often?
Let me address the persistency trends. As I said earlier, CRENESSITY has been an unusually steady medication where persistency is concerned, and it's clearly above average compared with other rare disease drugs. In fact, that ranks among the key growth drivers. Patient adds have been steady, reimbursement has been favorable, and persistency has been really strong, and Q3 was no different from earlier quarters. Naturally, we're hoping that continues in the future, even though the commercial ramp for CRENESSITY is still at an early stage, but nothing leads me to expect it will change going forward.
Yes; regarding VYKAT, I’d point you to roughly 250 milligrams as the average we’re observing per patient right now. So I think that’s a solid proxy that brings you to a WACC of about $550,000 annually.
This is So Youn speaking for Ash. Regarding VYKAT, what would be the most reliable approach to determine how often adverse effects are reported for this drug out in the real world? Looking at the FAERS database, we can see that both total AEs and serious AEs have risen for 2026 relative to 2025. Could you tell us whether that reflects growing use of the drug, or is it that the absolute frequency of AEs is actually higher in 2026 than it was in 2025? And then, if you could also give us your most recent perspective on VYKAT IP — how confident do you feel about the IP runway at this point? It looks as though the post-grant review of the 895 patent, brought by a generic challenger, was recently instituted and probably won't proceed to a PTAB trial. What outcome do you anticipate there?
Thanks for those questions. There are quite a few in there. So I'll do my best, and I think I may bring my colleagues in on the IP side. But let me begin with the questions you raised about adverse events. To return to safety being our main priority when it comes to patient safety < > medicines. And in the post-marketing setting, I think with respect to VYKAT XR, we benefit from having one specialized pharmacy that handles the supply of this medicine and offers a great deal of support around it, including the support our own commercial and medical team provides. In fact, we're in very close contact with patients and their prescribers as they are this medicine; so we can deliver the education that helps and is necessary to ensure appropriate patient selection, that dose titration happens in a safe and effective manner; and the label itself gives the guidance that's needed regarding side effects such as hyperglycemia and fluid that is known to be associated with diazoxide use. And so I think we have a well-controlled environment that enables patient support, along with support for their families and clinicians, as we go through that process.
And regarding IP — Kyle here — I'd say it's likely premature to get into any of the disputes around patents we already hold. That said, on our broader perspective on exclusivity, we've said before that we're feeling positive about that extending out to the mid-2040s for patents that are to be published and issued, and I believe we're confident in what we've got there.
I'm just curious about how you phrased things regarding working with the FDA when you bring up VYKAT XR — did that PWS and complex health issues study come about through those joint discussions, and they asked you to conduct it? Or is this something that you're literally putting forward that will definitely help the use of VYKAT XR in this patient population with high unmet need.
We came up with this proposal together with several leading experts in the field; and in my view it speaks to the fact that, since this is the first and only approved medicine for treating hyperphagia and Prader-Willi syndrome, people wanted to grasp how wide a population this medicine could effectively serve, going beyond the individuals enrolled in the clinical trial program that supported registration. So, alongside these KOLs, Dr. Jennifer Miller included, we are putting the finishing touches on that study's design, and we're also very pleased that Dr. Miller has gone ahead and published a piece offering direction on how VYKAT XR can be used across a wider group of patients in real-world conditions; that material is already something we draw on to back the community as we carry out education in the field.
I believe Samir touched on a few pieces of this already, but with Cobenfy's launch in schizophrenia having been somewhat muted, does that shift your view of the market for direclidine in schizophrenia at all? And what would you most want to see in Phase III that would get you excited about how the product's competitive profile looks in the schizophrenia market?
Thanks, Sumant. It's Samir here. Let me begin with what the bar is for the Phase III study — really, a positive study is what we're after. In psychiatry, what we've observed is that medicines which get across the finish line typically see strong, high uptake, especially when they carry a novel mechanism of action, and we believe our M4 selective orthosteric agonist does. Where we're really going to win here is on safety and tolerability; we've got a drug given once-daily with no titration; and looking at the Phase II data, we saw limited GI side effects compared with placebo. We think this is going to be a best-in-class, very convenient, easy-to-use medicine for patients with schizophrenia, offering a novel mechanism in a patient population that hasn't had many treatments for several years here. So we're very excited about the first study data coming next year. Eiry, anything you'd like to add there?
No. The sole point I would make is that we're still progressing very nicely with the Phase III program. And regarding what Samir noted about how important safety and tolerability are here, I'd say this in relation to that program: we've held a number of DMC meetings to review safety and tolerability across the program. And none of those has required us to make changes to the program. And then, if you look at discontinuation — which we know is an issue for Cobenfy given some of the tolerability issues seen there — we have a low discontinuation rate of 3% or less in our current program. So we're very confident about the profile we're seeing there.
I'd like to go back to something that came up initially during your R&D Day in San Diego last year — namely your early obesity program. Could you offer some commentary on the 2 programs, the CRF2 and the GGG? How are you viewing them from a development standpoint? Is it essentially a bake-off between the 2? Will they target different patient populations? And what would you need to see in the early Phase I data to decide how to advance one or both of those programs?
No, I appreciate the question. This is Kyle. So NBIP-2118 is our leading CRF2 agonist. This is a peptide injectable given under the skin, taken at minimum once per week, and we're creating it as an obesity treatment. Preclinical research shows it has plenty of favorable attributes. Naturally, we have to reproduce those results in humans, and honestly our near-term priority is launching a trial in obese but otherwise healthy volunteers to determine whether we can achieve a comparable profile to what the preclinical work showed. What we're aiming for here, though, is weight reduction on par with the incretins while ensuring the quality of that loss—meaning the pounds shed come from fat rather than muscle, so that muscle mass is preserved. Beyond that, preclinical work has shown further advantages in the cardiac and renal areas that might give us some differentiating properties — though certainly not by way of the GLP pathway. We're likewise pursuing a more favorable safety and tolerability profile, so there's a lot to like about the mechanism. And obviously, we know a great deal about CRF1 and 2 do as accompanying, and we're able to leverage that going forward. Where GGG — or our GGG program, which is NBIP-1968 — comes into play is a mix-and-match type of strategy. We recognize that in actual use, mechanisms get paired together, and that's likely where this field will head eventually; therefore, owning our own GGG matters for our program. We've got it as a standalone medicine that can be paired with 2118, and we've additionally combined it into an univalent molecule that might work as a single medicine to advance as well. So what we have excites us. But at this moment, the focus is entirely on entering the obese population and determining whether we can reproduce that earlier profile. What we have at this stage of the program genuinely excites us, and being here is thrilling.
Fine. Todd here, Sean — feel free to ring me afterward. Next question, please.
Tyler here, filling in for Danielle. Now that the salesforce build-out has been running for a couple of quarters, how much of the latest growth is attributable to that investment? And does meaningful productivity upside still lie ahead?
I take it you mean INGREZZA. Clearly, we posted robust growth in Q2 and Q3 following the rollout of the larger sales team. That said, our historical experience shows it takes several quarters before the expansion's full effect is felt or visible. So my expectation is that Q4 will show a greater contribution from the sales force, and that this carries into 2027. As we mentioned earlier on this call, we do anticipate double-digit growth next year, partly because of the sales force expansion.
Regarding PWS, could you give us more detail on how VYKAT's growth path will look through Q4 2027, in terms of patient starts and discontinuation rates? Should we be looking for meaningful sequential growth from the fourth quarter into 2027? Or is it more likely to come in the second half of the year?
Yes. What I'd say is, first off, we clearly see substantial potential in this medicine, and many patients with hyperphagia and PWS remain untreated. In light of recent external events, we do believe the growth trajectory we're anticipating will be delayed somewhat. Still, I think we're taking the right steps on the education front and on the promotional front to keep driving growth for this medicine. So we feel good about what VYKAT can do in hyperphagia. And this quarter was a growth quarter for us. As I mentioned earlier, each quarter we want to see more patients on than in the quarter before.
Congratulations on the quarter. So perhaps one about 569 in Alzheimer's psychosis: what would you need to observe in Phase I regarding both efficacy and safety before progressing to Phase II? And given that elderly patients tend to be more sensitive to muscarinic side effects, how are you approaching dosing and titration for this population?
Honestly, it's a bit early to know what we'll see when it comes to dosing — especially whether dose titration is even needed. I mean, that hasn't been the situation for other muscarinic agonists so far. So to address that last point first: we're still in Phase I. Much of the Phase I work, as you know, centers on understanding safety and tolerability and helping us select the right dose for a Phase II study. So at present, we're working through that. I'd say 569 has been well tolerated in the patient population so far, and we're achieving the dosing regimen we need for moving into the next stage of development. But obviously, we won't know for sure until that work is complete.
Another point about the obesity franchise, 1968 and 2118. Sorry if I missed this already, but what is the scientific reasoning for pairing a CRF2 agonist together with the GGG agonist? And then, kind of connected to that, how much R&D spending are you prepared to put into obesity, considering the other activity in psychiatry? I'm just curious whether you could say a little more on that.
On R2 in 2118 and 1968, I believe we understand where we are in development, and many questions are still open regarding how R2 could do as a monotherapy or maybe more effectively paired with an incretin of the GGG class at lower doses. So we'll find those things out early. That flows nicely into your second question, about obesity studies and spending. Our perspective is that we've got a solid mix across the types of programs we put money into, especially in neurology and psychiatry. In those areas, we have to fund everything through Phase III before we can identify our winners and get a full picture of how they perform. When it comes to obesity programs, what early development gives us includes things such as biomarkers, objective endpoints, and the chance to spot efficacy potential as soon as Phase I, provided you have patients who are healthy volunteers. We think there's a solid chance here to figure out which programs are ready to advance into later-stage Phase II and Phase III development, and to understand how those profiles compare with—or differ from—our psychiatry program. That gives us a smart way to diversify Neurocrine strategically. I'm choosing that word "strategically" on purpose, since we're building on the broader foundation we've already established with CRENESSITY and endocrinology, and we're heading into the biology we already understand in CRF.
This is Poorna calling in for Ami. Congratulations on the quarter. Regarding CRENESSITY, how much room is there to grow within the core adult population? And what approach are you taking to reach those patients? Also, what further share of the market could you capture with the study in ages under 4?
Sorry, could you clarify which population you meant?
The ages under 4.
For the male?
Yes, the male of those.
Right. So clearly there's substantial headroom among adults; and as I mentioned earlier when answering another question, we've reached a stage now where about half of the patients receiving treatment are adults, with a slight tilt toward females. So a great deal of opportunity remains really across every one of the different patient populations, roughly 15% — more than 15% at this point of the overall classic CAH populations are on treatment. And we're just about 7 quarters into the launch; so there's a long way to go and plenty of headroom here. I'll let Eiry speak to the opportunity below 4.
Yes, we are just beginning our trial in patients younger than 4 years old. And I mean, the thinking, I believe, is that to get the hypothalamic adrenal axis under control as quickly as possible, being able to use CRENESSITY as early as possible would be advantageous, since we know that even in those very young patients below age 4, there is often a requirement for very high steroid dosing, and the effect that this has on growth, bone development and other developmental features really from the start is — can be very harmful for patients. And so that is why we are very eager to get that study up and running. We are working on it now with the aim of being able to expand the label to an earlier age group.
Congratulations on the quarter and on all the progress. I'd like to ask about CRENESSITY and its growth outlook. When you look ahead over the coming several years, could you remind us how you've been thinking about the possible effect of competition — in particular the Vertex, Crinetics candidate for CAH — and although I understand there's no Phase III data for that asset yet, what are your thoughts on how the 2 assets might be differentiated? And what does your market research indicate about BID dosing, which you have, versus QD dosing?
Yes. This is Kyle. Thanks for the question. This is one of those cases where I enjoy discussing competition, because it lets me highlight all the strong data we have. CRENESSITY has truly established a very high bar, both for competitors and for our own next-generation pipeline programs. That's actually a concern for me, since we're investing in those pipeline programs right now. But when you consider efficacy, safety and tolerability, we now have patients out to 5 years in our long-term data; from our 2-year data, which is becoming a 3-year data set that we'll be able to publish, 70% of patients are on a physiological dose of their GC, and 70% of patients have normal androgen levels. We've observed sustained control of ACTH and cardiometabolic improvements, along with gains in pediatric growth trajectory. So there's a great deal to be encouraged about with CRENESSITY, and Eiry and her team did a fantastic job guiding those teams through a very simple and broad label that lets us treat pediatrics and the adult patient population, and we have multiple formulations. So I feel genuinely good and pleased about where we stand, whether it's competition or our own next-generation medicines in the portfolio. I believe we have a truly excellent opportunity here to change the standard of care. And given the demand we're seeing, we have ample runway to do so over the next couple of years. So that's where our focus is for now.
This is Mal Hoffman, sitting in for Evan. I'd like to revisit the muscarinic asset in your pipeline. I noticed that 986, the M4 antagonist for movement disorders, has been discontinued; so I was wondering whether you could share a bit of detail — was that because of a safety or tolerability problem, or is it more of a broad strategic call on the pipeline?
Appreciate the question. So 986 was an M4 antagonist that was aimed at potential use in movement disorders, dystonia among them and possibly Parkinsonian tremor. We finished the Phase I program for that medicine, and beyond the PK and tolerability you could also examine pharmacodynamic markers. And when we looked at all of that data in aggregate, we didn't truly hit the bar we had set for ourselves to be willing to move into a Phase II study in Parkinsonian tremor. So for that reason, while we were doing our portfolio prioritization, we paused and discontinued development of that molecule at this time. There was no specific safety issue that by itself halted the program. It was essentially the aggregate review of all the data.
Sam here, filling in for David. I'll keep it short. Regarding CRENESSITY as you expand, how much of the practical difficulty now involves tapering glucocorticoids the right way? And what should we consider about the dynamics around prescribing and, I suppose, possibly limiting penetration later on? Thanks, and congratulations once more.
Yes. To me, that isn't a barrier to prescribing. In fact, I view it as the treatment's promise. The label certainly doesn't get specific about that process, and it's highly individualized from one patient to the next. A few months ago, we put out what was essentially an expert opinion piece about how to down-titrate the GCs in these patients. And I definitely believe that was warmly received by the community as a way of offering somewhat more guidance in the end, but I don't view it as a deterrent whatsoever. I think it's the promise. And honestly, we're seeing excellent results, as shown in the 2-year data that came out recently. Anything to add, Eiry?
It's genuinely encouraging, I think, to observe that a significant proportion — a majority of patients — are able to get to physiologic dosing. And that happens safely and effectively, with no danger of adrenal insufficiency, which is clearly the thing these patients worry about. So we've had no rise or problem regarding adrenal insufficiency, and that has been very encouraging. So, to Eric's point, I really do view this as the promise of the treatment rather than an impediment.
Thanks to all of you for being on today's call and for the great questions. As you've heard, we keep showing strength throughout our commercial business and our R&D pipeline. We're posting solid commercial results while moving forward an ever-wider and more innovative pipeline of potential new medicines. In fact, we're still on schedule to deliver 6 Phase Is as well as 5 new Phase II starts during this year. At no point in Neurocrine's 35-year history have we reached this degree of R&D productivity within one year. So with that, thanks once more for your ongoing interest, and I'm eager to meet with many of you at the investor conferences still to come this year and definitely at our R&D Day next month. Thanks again.
Thanks. That takes us to the close of today's meeting. We're grateful for the time you spent with us and for taking part. You can go ahead and disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Neurocrine Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Neurocrine Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.